This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Droxidopa	The therapeutic efficacy of Droxidopa can be increased when used in combination with Thenalidine.
Ephedrine	The therapeutic efficacy of Ephedrine can be increased when used in combination with Thenalidine.
Epinephrine	The therapeutic efficacy of Epinephrine can be increased when used in combination with Thenalidine.
Levonordefrin	The therapeutic efficacy of Levonordefrin can be increased when used in combination with Thenalidine.
Norepinephrine	The therapeutic efficacy of Norepinephrine can be increased when used in combination with Thenalidine.

Food Interactions

Not Available

Products

: Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands: Sanbosten / Sandostene

Chemical Identifiers

UNII: 6U94N2D00F
CAS number: 86-12-4
InChI Key: KLOHYVOVXOUKQI-UHFFFAOYSA-N
InChI: InChI=1S/C17H22N2S/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15/h2-8,13,16H,9-12,14H2,1H3
IUPAC Name: 1-methyl-N-phenyl-N-[(thiophen-2-yl)methyl]piperidin-4-amine
SMILES: CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1

References

General References

Not Available

External Links

PubChem Compound: 27901
PubChem Substance: 46504731
ChemSpider: 25957
ChEBI: 135187
ChEMBL: CHEMBL2105458
ZINC: ZINC000000002146
Wikipedia: Thenalidine

Clinical Trials

Clinical Trials Clinical Trial & Rare Diseases Add-on Data Package Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	96 °C	PhysProp
boiling point (°C)	159 °C at 2.00E-02 mm Hg	PhysProp

Predicted Properties

Property	Value	Source
Water Solubility	0.0883 mg/mL	ALOGPS
logP	4.47	ALOGPS
logP	3.75	Chemaxon
logS	-3.5	ALOGPS
pKa (Strongest Basic)	8.69	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	6.48 Å²	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	87.44 m³·mol^-1	Chemaxon
Polarizability	32.89 Å³	Chemaxon
Number of Rings	3	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9679
Blood Brain Barrier	+	0.9862
Caco-2 permeable	+	0.6921
P-glycoprotein substrate	Substrate	0.6784
P-glycoprotein inhibitor I	Non-inhibitor	0.7908
P-glycoprotein inhibitor II	Non-inhibitor	0.542
Renal organic cation transporter	Inhibitor	0.7914
CYP450 2C9 substrate	Non-substrate	0.7078
CYP450 2D6 substrate	Substrate	0.5511
CYP450 3A4 substrate	Non-substrate	0.5881
CYP450 1A2 substrate	Inhibitor	0.6618
CYP450 2C9 inhibitor	Non-inhibitor	0.8589
CYP450 2D6 inhibitor	Inhibitor	0.8765
CYP450 2C19 inhibitor	Non-inhibitor	0.7584
CYP450 3A4 inhibitor	Non-inhibitor	0.9589
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.5834
Ames test	Non AMES toxic	0.8307
Carcinogenicity	Non-carcinogens	0.9578
Biodegradation	Not ready biodegradable	0.9913
Rat acute toxicity	2.4636 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.771
hERG inhibition (predictor II)	Inhibitor	0.6166

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-a79ba6bf2f3a2f82fbfa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-102a409e3e0c058e6189
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000i-3890000000-7adc1d7fb7f9eec4851d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-0ce14139273174530e90
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9510000000-fb5e46014e2d06a8f1de
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0wa0-2930000000-896cdcb951efb7085ddc
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	171.9160397	predicted	DarkChem Lite v0.1.0
[M-H]-	164.13934	predicted	DeepCCS 1.0 (2019)
[M+H]+	172.2117397	predicted	DarkChem Lite v0.1.0
[M+H]+	166.49734	predicted	DeepCCS 1.0 (2019)
[M+Na]+	172.1862397	predicted	DarkChem Lite v0.1.0
[M+Na]+	172.5905	predicted	DeepCCS 1.0 (2019)

Drug created at September 11, 2007 20:30 / Updated at February 21, 2021 18:51

Thenalidine

Identification

Structure for Thenalidine (DB04826)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)